Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.
Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.
Technavio's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Epilepsy Drugs Market in Europe 2015-2019
Technavio recognizes the following companies as the key players in the Epilepsy Drugs Market in Europe: Eisai, UCB Pharma, Pfizer and GlaxoSmithKline
Other Prominent Vendors in the market are: AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, and Valeant Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “Reformulated medicines usually have better tolerability, reduced dosing regimen, and decreased developmental costs than original drugs. Few vendors are focusing on developing such drugs instead of manufacturing new drugs. For instance, Neurontin by Pfizer, Keppra by UCB, and Trobalt by GlaxoSmithKline are film-coated tablets that were recently launched in the market.”
According to the report, growing patient population will lead to an increase in the consumption of anti-epileptic drugs. The market has significant levels of unmet medical needs. Currently, there are no safe and efficient disease-modifying drugs present in the market. Available drugs have many side effects, which decreases patient compliance. Any drug that can completely cure the disease will drive the market.
Further, the report states that patent expiries of major branded drugs will decrease their market sales. This will decrease the market revenue of innovator drugs, paving the way for their generic forms.
Eisai, UCB Pharma, Pfizer, GlaxoSmithKline, AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals.